DUSA PHARMACEUTICALS, INC.
NASDAQ : DUSA

DUSA PHARMACEUTICALS, INC.

October 23, 2006 06:30 ET

DUSA Pharmaceuticals, Inc. to Host Third Quarter Corporate Highlights and Financial Results Conference Call

WILMINGTON, MASSACHUSETTS--(CCNMatthews - Oct. 23, 2006) - DUSA Pharmaceuticals, Inc. (NASDAQ GM:DUSA) announces that its third quarter corporate highlights and financial results press release will be issued on Friday, November 3 at 6:30 a.m. to be followed by a conference call at 8:30 a.m.



Friday, November 3 - 8:30 a.m. Eastern
If calling from the US or Canada use the following toll-free number:
800.647.4314
Password - DUSA

For International callers use
641.297.7663
Password - DUSA

A recorded replay of the call will be available by 12:00 pm
North American callers 877.863.0350
International callers 858.244.1268


The call will be accessible on our web site after 1:00 p.m. www.dusapharma.com.

DUSA Pharmaceuticals, Inc. is an integrated dermatology specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of pre-cancerous actinic keratoses, and is being developed for the treatment of acne and photodamage. DUSA's other dermatology products include Nicomide®, and the AVAR® line, resulting from its merger with Sirius Laboratories, Inc. These products target patients with acne and rosacea. DUSA is also developing certain internal indications of Levulan PDT. DUSA is based in Wilmington, MA. Please visit our website at www.dusapharma.com.


Contact Information

  • DUSA Pharmaceuticals, Inc.
    Shari Lovell
    Director, Shareholder Services
    (416) 363-5059
    416.363-6602 (FAX)
    Website: www.dusapharma.com